Clear cell renal carcinoma has a modest tumor mutational burden and increased infiltration of CD8+ T cells which is associated with worse prognosis in this disease. Biomarkers for response to immune checkpoint inhibitors are needed to predict which patients will respond. David Braun joins Alicia Morgans and overviews his ASCO 2020 presentation on the genomic and immune determinants of response to PD-1 axis blockade in advanced clear cell renal carcinoma using tumor samples from patients enrolled in three prospective trials: Checkmate 009, Checkmate 010, and CheckMate 025. These three trials ultimately led to the FDA approval of nivolumab for VEGF-refractory kidney cancer. Biographies:
David Braun, MD, Ph.D., the John R. Svenson Fellow in Oncology at the Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Fellow Brigham and Women’s Hospital, and Massachusetts General Hospital, Boston, MA.
Alicia Morgans, MD, MPH, Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.